Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Formulations and Active Pharmaceutical Ingredients (APIs). Qilu currently has 13 subsidiaries, 11 manufacturing sites and over 3,500 employees worldwide. It ranks among Top 10 in Chinese pharmaceutical industry by sales revenue in 2021. Dedicated to offering high-quality & trustworthy medicines to the world and improving people‘s well-being, Qilu is vigorously exporting its products to over 90 countries and regions.
Products Marketed in China
Pharmaceutical Companies In China
We continue to strengthen our R & D capabilities to build a robust and diversified portfolio for a sustainable business. Qilu always maintains an innovative development strategy and is achieving its organic growth leveraging its robust pool of over 3,500 scientists spread across 5 R & D centers based in the US (Seattle, Boston, San Francisco) and China (Shanghai, Jinan). To date, Qilu has launched over 300 products with over 55 products “First-to-Launch” in China. The company has also fostered a robust pipeline including over 200 generic products, over 30 biosimilars and over 90 innovative products.
Qilu always commits itself to offering high-quality & trustworthy medicines to the world and improving people’s well-being. It is the first Chinese company to obtain both USFDA and EDQM approval for sterile APIs. Its Finished Formulations and APIs have been approved by USFDA, EMA, TGA, MHRA, PMDA, etc.
Qilu maintains a robust and sustainable growth in global markets while consistently foraying into new geographies to further fortify its position globally. With a well-established domestic and overseas sales network, you may find Qilu’s footprints across the world.